Table 4 Qualitative description of metabolic syndrome subcomponents prevalence within included studies
Author and publication year | Hypertension | Diabetes | Visceral obesity | High triglycerides | Low HDL cholesterol | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
HIV+ | HIV− | HIV+ | HIV− | HIV+ | HIV− | HIV+ | HIV− | HIV+ | HIV− | ||
1 | Amusa et al., 2016 [33] | 46.0% P < 0.01 | 5/50 (10.0%) P < 0.01 | 42/150 (28.0%) P < 0.01 | 2/50 (4.0%) P < 0.01 | 48/150 (32.0%) P 0.79 | 15/50 (30%) P 0.79 (P = 0.79) | NP | NP | NP | NP |
2 | Ayodele et al., 2012 [32] | 82 (28.2%), P = 0.146 | NP | 54 (18.6%) P = 0.600 | NP | 56 (19.2%) P < 0.001 | NP | 38 (13.1%) P = 0.880 | NP | 159 (54.6) P = 0.013 | NP |
3 | Berhane et al., 2012 [34] | 110/313 (35.1%) | NP | 78/313 (24.9%) | 43/313 (13.7%) | 83/31 (26.5%) | NP | ||||
4 | Tesfaye et al., 2014 [42] | SBP = 39/374 DBP = 33/374 | NP | 103 | NP | NP | NP | 154 | NP | 248 | NP |
5 | Sobieszczyk et al., 2016 [29] | NP | NP | (0.7 to 1.9%) P = 0.346 | 33.5 to 44.3% (P = 0.060) | 9.4 to 13.3%, P = 0.112 | 56.6 to 61.0%, P = 0.283 | ||||
6 | Obirikorang et al., 2016 [41] | NP | NP | NP | NP | NP | NP | NP | NP | NP | NP |
7 | Ngatchou et al., 2013 [40] | NP | NP | 26% P < 0.01 | 1% P < 0.01 | NP | NP | NP | NP | NP | NP |
8 | Fourie et al., 2010 [35] | 50.0% P = 0.03 | 59.0% P = 0.03 | ATP III 22.7% P = 0.49 IDF 36.6% P = 0.08 | ATP III 25.1% P = 0.49 IDF 43.7% P = 0.08 | ATP III Male—0.9% P = 0.32 Female—18.3% P = 0.93 IDF Male—2.6% P = 0.31 Female—33.9% P - 0.22 (P = 0.22) | ATP III Male—0.0% P - 0.32 (P = 0.32) Female—18.7% P - 0.93 (P = 0.93) IDF Male—0.9% P - 0.31 (P = 0.31) Female—40.1% P - 0.22 (P = 0.22) | ATP III 18.2% P = 0.19 IDF 14.3% P = 0.19 | ATP III 17.6% P = 0.28 IDF 14.3% P = 0.28 | ATP III Male—47.4%, Female—62.6% P < 0.0001 IDF Male—46.5% P < 0.0001 Female—62.6% P < 0.0001 | ATP III Male—12.1% P < 0.0001 Female—33.7% P < 0.0001 IDF Male—11.2% P < 0.0001 Female—33.7% P < 0.0001 |
9 | Muhammad et al., 2013 [45] | 9.5 (P < 0.001). | NP | 3 (P = 1.0) | NP | NP | NP | 16 | 68.5% | ||
10 | Mbunkah et al., 2014 [38] | 24.7% | NP | NP | NP | NP | NP | NP | NP | NP | NP |
11 | Guehi et al., 2016 [30] | 37 (4.9%) | NP | 4 (0.5%) | NP | 128 (17.0%) | NP | 128 (17.0%) | NP | NP | NP |
12 | Mashinya et al., 2015 [37] | 56 (26.2%) | NP | 10 (4.7%) | NP | NP | NP | Male = 35.0 vs female = 12.5%, P = 0.001) | 91 (43.8%) | ||
13 | Guira et al., 2016 [31] | 36 (66.7%) | NP | 16 (29.6%) | 27 (50%) | 37 (68.5%) | |||||
14 | Hirigo et al., 2016 [36] | 18/185 P = 0.84 | NP | IDF criteria 58 (31.3%) | NP | NP | NP | NP | NP | NP | NP |
15 | Zannou et al., 2009 [28] | 29 (42.6) | 6 (7.6%) | 24 (33.3%) | NP | 10 (14.1%) | NP | NP | NP | ||
16 | Muyanja et al., 2016 [39] | 13 (5.2%) P = 0.46 | NP | NP | NP | NP | NP | 74 (29.6%) 0.76 | NP | 214 (85.6%) 0.16 | NP |
17 | Adébayo et al., 2015 [44]* | 60 (24.6%) | 5 (10%), P < 0.01 | 5 (2.04%) | 2 (4.0%) | NP | NP | 44 (18.0%) Male—12 (12.6%) Female—26 (13.3%) | NP | NP | NP |
18 | Sawadogo et al., 2005 [43]* | NP | NP | 1.3%, CI (0.5–3.0) | NP | NP | NP | NP | NP | NP | NP |